WY14643 Attenuates the Scopolamine-Induced Memory Impairments in Mice

被引：0
作者：
Hui Xu
Zhengchen You
Zhonghua Wu
Liang Zhou
Jianhong Shen
Zhikai Gu
机构：
[1] The Sixth People’s Hospital of Nantong,Department of Neurosurgery
[2] Affiliated Hospital of Nantong University,Department of Neurosurgery
[3] The First Affiliated Hospital of Soochow University,Department of Neurosurgery and Brain and Nerve Research Laboratory
来源：
Neurochemical Research | 2016年 / 41卷
关键词：
Brain-derived neurotrophic factor; cAMP response element-binding protein; Memory; Scopolamine; WY14643;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
WY14643 is a selective agonist of peroxisome proliferator-activated receptor-α (PPAR-α) with neuroprotective and neurotrophic effects. The aim of this study was to evaluate the effects of WY14643 on cognitive impairments induced by scopolamine, a muscarinic acetylcholine receptor antagonist. We conducted different behavior tests including the Y-maze, Morris water maze, and passive avoidance test to measure the cognitive functions of C57BL/6J mice after scopolamine and WY14643 treatment. It was found that WY14643 injection significantly attenuated the scopolamine-induced cognitive impairments in these behavioral tests. Moreover, WY14643 treatment significantly enhanced the expression of brain-derived neurotrophic factor (BDNF) signaling cascade in the hippocampus. The usage of both PPAR-α inhibitor GW6471 and BDNF system inhibitor K252a fully prevented the memory-enhancing effects of WY14643. Therefore, these findings suggest that WY14643 could improve the scopolamine-induced memory impairments, and these effects are mediated by the activation of PPAR-α and BDNF system, thereby exhibiting a cognition-enhancing potential.
引用
收藏
页码：2868 / 2879
页数：11
相关论文
共 200 条
[1]  
Schonberger SJ(2001)Proteomic analysis of the brain in Alzheimer’s disease: molecular phenotype of a complex disease process Proteomics 1 1519-1528
[2]  
Edgar PF(2007)Forecasting the global burden of Alzheimer’s disease Alzheimers Dement 3 186-191
[3]  
Kydd R(2011)The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics Nat Rev Drug Discov 10 698-712
[4]  
Faull RL(1983)Alzheimer’s disease: a disorder of cortical cholinergic innervation Science 219 1184-1190
[5]  
Cooper GJ(2000)Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors Curr Med Chem 7 303-339
[6]  
Brookmeyer R(2011)The cholinergic system in aging and neuronal degeneration Behav Brain Res 221 555-563
[7]  
Johnson E(2009)Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer’s disease Pharmacol Biochem Behav 91 554-559
[8]  
Ziegler-Graham K(2013)Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease Neurotox Res 24 358-369
[9]  
Arrighi HM(2010)Drugs for Alzheimer’s disease: are they effective? P T 35 208-211
[10]  
Karran E(2005)Endogenous BDNF is required for long-term memory formation in the rat parietal cortex Learn Mem 12 504-510
12345678910